Wang Liu-Ding, Xu Zhen-Min, Liang Xiao, Qiu Wen-Ran, Liu Shao-Jiao, Dai Ling-Ling, Wang Ye-Fei, Guo Chun-Yan, Qi Xiang-Hua, Wang Jian, Ding Yan-Bing, Zhang Yun-Ling, Liao Xing
Xiyuan Hospital, China Academy of Chinese Medical Sciences Beijing 100091, China Center for Evidence-based Chinese Medicine, Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences Beijing 100700, China.
Graduate School, Beijing University of Chinese Medicine Beijing 100029, China.
Zhongguo Zhong Yao Za Zhi. 2021 Jun;46(12):2963-2971. doi: 10.19540/j.cnki.cjcmm.20210325.501.
To overview the systematic reviews of Panax notoginseng saponins in the treatment of acute cerebral infarction. CNKI, CBM, Wanfang, VIP, PubMed, Cochrane Library and EMbase databases were retrieved to collect the systematic reviews of the efficacy of P. notoginseng saponins in the treatment of acute cerebral infarction. The retrieval time was from the time of database establishment to January 2021. After two researchers independently screened out the literature and extracted the data, AMSTAR-2 scale was used to evaluate the methodological quality of the included systematic reviews, GRADE system was used to grade the quality of evidences of the outcome indicators, and the efficacy evaluation was summarized. A total of 5 systematic reviews were included. AMSTAR-2 evaluation results showed that 3 items were relatively complete, while 4 items had a poor overall quality. P. notoginseng saponins combined with conventional Western medicine therapy was superior to single conventional therapy in the recovery of neurological function, enhancement of the total effective rate in clinic, and improvement of activities of daily living. GRADE evaluation results showed that the quality of evidence was from low quality to very low quality. In conclusion, in the treatment of acute cerebral infarction, P. notoginseng saponins can improve the clinical efficacy, with a good safety but a not high methodological quality and a low evidence quality. It is suggested that high-quality clinical studies shall be further carried out to provide evidence-based basis for the application of P. notoginseng saponins in the treatment of acute cerebral infarction.
综述三七总皂苷治疗急性脑梗死的系统评价。检索中国知网、中国生物医学文献数据库、万方数据库、维普数据库、PubMed、Cochrane图书馆和EMbase数据库，收集三七总皂苷治疗急性脑梗死疗效的系统评价。检索时间为各数据库建库至2021年1月。由两名研究人员独立筛选文献并提取数据，采用AMSTAR-2量表评价纳入系统评价的方法学质量，采用GRADE系统对结局指标的证据质量进行分级，并汇总疗效评价情况。共纳入5篇系统评价。AMSTAR-2评价结果显示，3项相对完整，4项整体质量较差。三七总皂苷联合西医常规治疗在神经功能恢复、提高临床总有效率及改善日常生活活动能力方面优于单纯西医常规治疗。GRADE评价结果显示，证据质量从低质量到极低质量。综上所述，在急性脑梗死治疗中，三七总皂苷可提高临床疗效，安全性良好，但方法学质量不高，证据质量较低。建议进一步开展高质量临床研究，为三七总皂苷治疗急性脑梗死的应用提供循证依据。
